Indicated for adults who have completed the initial 4-week course of 2.5 mg: 🍬 Type 2 Diabetes Mellitus: To improve glycemic control. ⚖️ Chronic Weight Management: For obesity or overweight individuals with weight-related comorbidities.

Dosage and administration

Packaging: Single-dose Vial (5 mg / 0.5 ml). ⚠️ DOSAGE PROTOCOL (Step 2): 💉 5 mg Dose: Inject subcutaneously once weekly. Typically prescribed for weeks 5-8 of treatment. 🛑 Warning: DO NOT start therapy with 5 mg. Patients must complete 4 weeks on 2.5 mg first to mitigate severe gastrointestinal distress. 📍 Storage: Keep refrigerated at 2°C to 8°C (36°F to 46°F).

Personal or family history of Medullary Thyroid Carcinoma (MTC). Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pregnancy and breastfeeding. Severe gastrointestinal disease (e.g., gastroparesis).

Side effects may re-emerge during dose escalation: 🤢 Gastrointestinal: Nausea, vomiting, diarrhea, constipation (usually transient). ⚠️ Pancreatitis: Risk of inflammation of the pancreas. Hypoglycemia (if used with Sulfonylureas or Insulin).

Mounjaro 5 — Tirzepatide 5 mg / 0.5 ml, 1 pcs, Eli Lilly

100% original product

Active ingredient

Tirzepatide

Storage temperature

Cold chain · Storage +2…+8 °C

Shipped in a thermal box with cold packs

Manufacturer

Eli Lilly

Dosage

5 mg / 0.5 ml

Dosage form Concentrate for solution for infusion

Vials per pack 1

Mounjaro 5 mg (Tirzepatide) 5 mg/0.5 mL Cold chain · Storage +2…+8 °C

Name: Mounjaro 5
Brand: Eli Lilly
SKU: PROD-117
Price: 4000 UAH
Availability: OutOfStock

4000₴ ~~4494₴~~ -11% Out of stock

Cold chain Storage +2…+8 °C

This medicine requires temperature control. We pack it in a thermal box with cold packs for safe delivery.

Please return the thermal box with cold packs after delivery. An additional charge applies only if you wish to keep the box.

Mounjaro 5 mg (Tirzepatide 5 mg) is the first therapeutic maintenance dose of the dual GIP/GLP-1 receptor agonist.

Manufacturer: Eli Lilly (India). This 5 mg vial represents Step 2 in the dosage escalation protocol. Unlike the 2.5 mg starter dose, the 5 mg dose is considered clinically effective for glycemic control and initiates more significant weight loss results.

Mechanism of Action ("Metabolic Reset"):

By activating both GIP and GLP-1 receptors, Tirzepatide 5 mg provides a stronger signal to the brain to stop eating and increases insulin sensitivity significantly. It effectively lowers fasting and post-meal glucose levels while promoting substantial calorie deficit through appetite suppression.

✅ Key Benefit: Marked improvement in HbA1c levels and accelerated body weight reduction compared to the starting dose.

Indicated for adults who have completed the initial 4-week course of 2.5 mg:

🍬 Type 2 Diabetes Mellitus: To improve glycemic control.
⚖️ Chronic Weight Management: For obesity or overweight individuals with weight-related comorbidities.

Packaging: Single-dose Vial (5 mg / 0.5 ml).

⚠️ DOSAGE PROTOCOL (Step 2):

💉 5 mg Dose: Inject subcutaneously once weekly. Typically prescribed for weeks 5-8 of treatment.
🛑 Warning: DO NOT start therapy with 5 mg. Patients must complete 4 weeks on 2.5 mg first to mitigate severe gastrointestinal distress.
📍 Storage: Keep refrigerated at 2°C to 8°C (36°F to 46°F).

Personal or family history of Medullary Thyroid Carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pregnancy and breastfeeding.
Severe gastrointestinal disease (e.g., gastroparesis).

Side effects may re-emerge during dose escalation:

🤢 Gastrointestinal: Nausea, vomiting, diarrhea, constipation (usually transient).
⚠️ Pancreatitis: Risk of inflammation of the pancreas.
Hypoglycemia (if used with Sulfonylureas or Insulin).

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.06.2026

Active ingredient

Tirzepatide